Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TNG908 in MTAP-deleted Advanced or Metastatic Solid Tumors
NCT05275478Phase 2Terminated
- Sponsor
- Tango Therapeutics
- Start
- Mar 2022
- Primary completion
- Dec 2025
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of TNG908 in solid tumor, non-small cell lung cancer (NSCLC), mesothelioma, pancreatic ductal adenocarcinoma (PDAC), sarcoma, sponsored by Tango Therapeutics. Started Mar 2022; status: terminated.
02
Drugs
TNG908
03
Conditions
solid tumornon-small cell lung cancer (NSCLC)mesotheliomapancreatic ductal adenocarcinoma (PDAC)sarcoma
Beyond the preview
Go deeper on NCT05275478.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05275478.